{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:51:29Z","timestamp":1787964689921,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejca.2020.07.037","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T19:24:39Z","timestamp":1600370679000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Biosimilars in oncology: Effects on economy and therapeutic innovations"],"prefix":"10.1016","volume":"139","author":[{"given":"Kai","family":"H\u00fcbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.07.037_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J Econ Perspect"},{"key":"10.1016\/j.ejca.2020.07.037_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2016.06.022","article-title":"The cost and burden of cancer in the European Union 1995-2014","volume":"66","author":"Jonsson","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.07.037_bib3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: a population-based cost analysis","volume":"14","author":"Luengo-Fernandez","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.07.037_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00103-018-2839-3","article-title":"[The health economics of cancer screening in Germany: which population-based interventions are cost-effective?]","volume":"61","author":"Schlander","year":"2018","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz"},{"key":"10.1016\/j.ejca.2020.07.037_bib5","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.07.037_bib6","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed: 3 Jan 2020."},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2020.07.037_bib7","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s11523-011-0196-3","article-title":"The economic pressures for biosimilar drug use in cancer medicine","volume":"7","author":"Cornes","year":"2012","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ejca.2020.07.037_bib8","author":"Quintiles"},{"key":"10.1016\/j.ejca.2020.07.037_bib9","unstructured":"Lauer-Taxe Online 4.0, CGM Lauer."},{"key":"10.1016\/j.ejca.2020.07.037_bib10","unstructured":"MabThera summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf. Accessed:."},{"key":"10.1016\/j.ejca.2020.07.037_bib11","unstructured":"Robert-Koch-Institut. Gemeinsame Publikation des Zentrums f\u00fcr Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland f\u00fcr 2013\/2014. 11. Ausgabe. Available at: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2017\/krebs_in_deutschland_2017.pdf;jsessionid=B894B978F02753E00DA24D406463ADCF.1_cid290?__blob=publicationFile. Accessed: 13 Jan 2020."},{"key":"10.1016\/j.ejca.2020.07.037_bib12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.07.037_bib13","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2020.07.037_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0092-8674(82)90065-4","article-title":"Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas","volume":"28","author":"Padhy","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2020.07.037_bib15","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.07.037_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2020.07.037_bib17","unstructured":"Tumorregister M\u00fcnchen. Tumorregister m\u00fcnchen. Spezielle auswertungen C50: mammakarzinom (frauen) \u00dcberleben ab metastase [online]. Available at: http:\/\/www.tumorregistermuenchen.de\/facts\/spec\/spec_C50f__08_20130207_met_her2. Accessed: 13 Feb 2013."},{"key":"10.1016\/j.ejca.2020.07.037_bib18","unstructured":"G-BA. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V Pertuzumab (Perjeta\u00ae), Modul 3A. Available at: https:\/\/www.g-ba.de\/downloads\/92-975-255\/2013-03-04_Modul3A_Pertuzumab.pdf. Accessed: 4 Mar 2013."},{"key":"10.1016\/j.ejca.2020.07.037_bib19","unstructured":"Statista. Mittelwerte von K\u00f6rpergr\u00f6\u00dfe, -gewicht und BMI bei Frauen in Deutschland nach Altersgruppe im Jahr 2011. Available at: https:\/\/de.statista.com\/statistik\/daten\/studie\/260916\/umfrage\/mittelwerte-von-groesse-gewicht-und-bmi-bei-frauen-nach-alter. Accessed: 15 Jul 2019."},{"key":"10.1016\/j.ejca.2020.07.037_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.07.037_bib22","series-title":"IMS pharmascope\/DKM","year":"2018"},{"key":"10.1016\/j.ejca.2020.07.037_bib23","first-page":"3295","article-title":"Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations","volume":"25","author":"Aapro","year":"2017","journal-title":"Support Care Canc"},{"key":"10.1016\/j.ejca.2020.07.037_bib24","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","article-title":"Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines","volume":"46","author":"Falandry","year":"2010","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.07.037_bib25","first-page":"911","article-title":"Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)","volume":"24","author":"Gascon","year":"2016","journal-title":"Support Care Canc"},{"key":"10.1016\/j.ejca.2020.07.037_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CP201633","article-title":"Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany","volume":"50","author":"Hadji","year":"2012","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ejca.2020.07.037_bib28","series-title":"Jahresbericht der zertifizierten Brustkrebszentren","year":"2019"},{"key":"10.1016\/j.ejca.2020.07.037_bib29","series-title":"IMS pharmascope\/DKM","year":"2019"},{"key":"10.1016\/j.ejca.2020.07.037_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdx690","article-title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial","volume":"29","author":"Mobus","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.07.037_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1078155211407367","article-title":"Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia","volume":"18","author":"Aapro","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2020.07.037_bib32","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2217\/fon-2017-0374","article-title":"Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz","volume":"13","author":"McBride","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.07.037_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13696998.2017.1358173","article-title":"Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia","volume":"20","author":"McBride","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.ejca.2020.07.037_bib34","series-title":"Delivering on the potential of biosimilar medicines. The role of functioning competitive markets","year":"2016"},{"key":"10.1016\/j.ejca.2020.07.037_bib35","unstructured":"Biosimilars in Zahlen. Marktdaten AG Pro Biosimimars 12\/2019. Available at: https:\/\/probiosimilars.de\/allgemein\/marktdaten-biosimilars-dezember-2019\/. Accessed: 25 Feb 2020."},{"key":"10.1016\/j.ejca.2020.07.037_bib36","unstructured":"The biosimilar market today and tomorrow. Available at: http:\/\/www.nxtbook.com\/nxtbooks\/advanstaruk\/pte_201008\/index.php#\/6\/OnePage. Accessed: 24 Jan 2020."},{"key":"10.1016\/j.ejca.2020.07.037_bib37","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen - Langversion 1.2, 2019, AWMF Registernummer: 032\/054OL. Available at: http:\/\/leitlinienprogramm-onkologie.de\/Supportive-Therapie.95.0.html. Accessed: 24 Jan 2020."},{"key":"10.1016\/j.ejca.2020.07.037_bib38","series-title":"DocCheck Research (im Auftrag von Pro Generika eV). Biosimilars aus \u00c4rztesicht. Awareness, Akzeptanz und Einsatz","year":"2018"},{"key":"10.1016\/j.ejca.2020.07.037_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000495145","article-title":"Position of scientific oncological societies towards biosimilar antibodies","volume":"14","author":"W\u00f6rmann","year":"2019","journal-title":"Breast Care"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:35Z","timestamp":1760732855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920304482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":37,"alternative-id":["S0959804920304482"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.07.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilars in oncology: Effects on economy and therapeutic innovations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}